Model to predict outcomes in kidney cancer with IVC wall invasion
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study uses information from scans and surgery findings to build a prediction model for people with kidney cancer that has grown into a major vein (the IVC). It aims to help doctors better estimate outcomes and guide care after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 or older).
- Your kidney cancer has a tumor in the IVC vein, and the vein wall is involved (known before or during surgery).
- You had approved imaging tests (ultrasound, contrast ultrasound, and/or contrast CT and MRI) before surgery.
- You had a radical nephrectomy (removal of the kidney) plus at least one type of vein/thrombectomy procedure.
- You can tolerate surgery and your health status is good (ECOG 0–2).
- You can return for follow-up visits, and you have no prior history of cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is checking how well a model can predict the outcomes for people with kidney cancer who have had surgery. It looks at your medical records after surgery to help doctors better understand your recovery and future risks.
This study uses a computer program (deep learning) to look at your kidney CT scan and tell if your cancer is more advanced (stage T3) or earlier (stage T1-T2). The goal is to help doctors plan the best treatment for you.
This trial tests if a combination of targeted embolization, immunotherapy (Toripalimab), and a targeted therapy pill (Axitinib) can shrink advanced kidney cancer before surgery. It is for patients whose cancer has spread to nearby tissues or lymph nodes, or has limited spread elsewhere that can be removed.
This trial tests two drugs, lenvatinib and pembrolizumab, given before surgery to shrink kidney cancer that has spread into the large vein carrying blood to the heart (the vena cava). The goal is to see if this approach makes surgery more effective and improves outcomes.
This Phase 2 trial tests whether pembrolizumab plus axitinib can shrink kidney cancer before surgery, when there is tumor growth into the inferior vena cava (IVC). It may help make the operation easier and improve chances of long-term control.
This study uses a computer model to analyze your CT scans and predict how long you might stay cancer-free after surgery. It aims to help doctors personalize follow-up care for clear cell kidney cancer.
Hear when a new Tumor Thrombus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.